Addition of 5-Azacitidine to Standard Induction Therapy Is Feasible In Older Patients with Acute Myeloid Leukemia: The AML-AZA Trial of the SAL Study Group.
Krug UO, Koschmieder A, Gerss J, Serve H, Steffen B, Bug G, Schaich M, Brandts C, Rollig C, Ehninger G, Duehrsen U, Noppeney R, Berdel WE, Koschmieder S, Muller-Tidow C
Research article (journal)Details about the publication
Journal: Blood (Blood)
Volume: 116
Issue: 21
Status: Published
Release year: 2010
Language in which the publication is written: English
Authors from the University of Münster
| Berdel, Wolfgang Eduard | Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A) |
| Gerß, Joachim | Institute of Biostatistics and Clinical Research (IBKF) |
| Koschmieder, Steffen | Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A) |
| Koschmieder, Anja | Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A) |
| Krug, Utz | Medical Clinic of Internal Medicine A (Hematology, Oncology, and Oneumology) (Med A) |